EC
NMRA icon

EntryPoint Capital’s Neumora Therapeutics NMRA Stock Holding History

EntryPoint Capital’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-110,875
Closed -$216K – 904
2026
Q1 		$216K Sell
110,875
-34,510
-24% -$89.4K 0.06% 612
2025
Q4 		$260K Buy
+145,385
New +$318K 0.1% 424
2025
Q1 		– Sell
-12,762
Closed -$135K – 863
2024
Q4 		$135K Buy
+12,762
New +$153K 0.06% 646

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

EntryPoint Capital's NMRA Position: Q2 2026 in Review

EntryPoint Capital sold out of Neumora Therapeutics (NMRA) in Q2 2026, closing a stake of 110,875 shares — an estimated $216K sold.

EntryPoint Capital first reported a position in NMRA in Q4 2024 and held it in 3 quarters. The position peaked at $260K in Q4 2025. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • EntryPoint Capital reported no remaining Neumora Therapeutics position as of Q2 2026 after selling out during the quarter.
  • EntryPoint Capital sold 110,875 Neumora Therapeutics shares in Q2 2026, an estimated $216K.
  • EntryPoint Capital first reported a position in Neumora Therapeutics in Q4 2024 and held it in 3 quarters.
  • EntryPoint Capital's Neumora Therapeutics position peaked at $260K in Q4 2025.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.